Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764161 | 0.80 | KDM4E (0.54) | HTTKDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL1189406 | 0.80 | CYP1A2 (0.52) | KDM4EALDH1A1CYP1A2HPGDHSD17B10 | |
| SCHEMBL1204668 | 0.80 | F2R (0.39) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1188502 | 0.78 | KDM4E (0.43) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12878973 | 0.77 | KDM4E (0.38) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1188236 | 0.74 | PDE10A (0.35) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1188704 | 0.72 | SMN1; SMN2 (0.57) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1204955 | 0.71 | MEN1 (0.37) | KDM4ECYP1A2CYP2C19HSD17B10MEN1 | |
| SCHEMBL1205158 | 0.71 | NPC1 (0.37) | HTTALDH1A1AKT1AKT2MEN1 | |
| SCHEMBL1205558 | 0.71 | AKT1 (0.39) | HTTKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2240487-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240486-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | HTT 3641/4885KDM4E 3015/4885ALDH1A1 1015/4885 |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | HTT 3506/4885KDM4E 3889/4885ALDH1A1 2097/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | HTT 3408/4885KDM4E 3850/4885ALDH1A1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.